RGLS
Price
$8.22
Change
+$0.12 (+1.48%)
Updated
Jun 6 closing price
Capitalization
560.8M
65 days until earnings call
XENE
Price
$31.64
Change
+$0.91 (+2.96%)
Updated
Jun 6 closing price
Capitalization
2.36B
60 days until earnings call
Interact to see
Advertisement

RGLS vs XENE

Header iconRGLS vs XENE Comparison
Open Charts RGLS vs XENEBanner chart's image
Regulus Therapeutics
Price$8.22
Change+$0.12 (+1.48%)
Volume$2.78M
Capitalization560.8M
Xenon Pharmaceuticals
Price$31.64
Change+$0.91 (+2.96%)
Volume$576.17K
Capitalization2.36B
RGLS vs XENE Comparison Chart
Loading...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGLS vs. XENE commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGLS is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (RGLS: $7.93 vs. XENE: $28.49)
Brand notoriety: RGLS and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGLS: 29% vs. XENE: 82%
Market capitalization -- RGLS: $560.8M vs. XENE: $2.36B
RGLS [@Biotechnology] is valued at $560.8M. XENE’s [@Biotechnology] market capitalization is $2.36B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGLS’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • RGLS’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both RGLS and XENE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGLS’s TA Score shows that 4 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • RGLS’s TA Score: 4 bullish, 4 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both RGLS and XENE are a good buy in the short-term.

Price Growth

RGLS (@Biotechnology) experienced а +0.13% price change this week, while XENE (@Biotechnology) price change was -6.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

RGLS is expected to report earnings on Aug 12, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.36B) has a higher market cap than RGLS($561M). RGLS YTD gains are higher at: 401.899 vs. XENE (-27.321). RGLS has higher annual earnings (EBITDA): -45.85M vs. XENE (-276.74M). XENE has more cash in the bank: 627M vs. RGLS (75.8M). RGLS has less debt than XENE: RGLS (274K) vs XENE (9.02M). RGLS (0) and XENE (0) have equivalent revenues.
RGLSXENERGLS / XENE
Capitalization561M2.36B24%
EBITDA-45.85M-276.74M17%
Gain YTD401.899-27.321-1,471%
P/E RatioN/AN/A-
Revenue00-
Total Cash75.8M627M12%
Total Debt274K9.02M3%
FUNDAMENTALS RATINGS
RGLS vs XENE: Fundamental Ratings
RGLS
XENE
OUTLOOK RATING
1..100
265
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
8351
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
3488
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGLS's Valuation (61) in the Pharmaceuticals Other industry is in the same range as XENE (75) in the Biotechnology industry. This means that RGLS’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (51) in the Biotechnology industry is in the same range as RGLS (83) in the Pharmaceuticals Other industry. This means that XENE’s stock grew similarly to RGLS’s over the last 12 months.

XENE's SMR Rating (94) in the Biotechnology industry is in the same range as RGLS (98) in the Pharmaceuticals Other industry. This means that XENE’s stock grew similarly to RGLS’s over the last 12 months.

RGLS's Price Growth Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for XENE (88) in the Biotechnology industry. This means that RGLS’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for RGLS (100) in the Pharmaceuticals Other industry. This means that XENE’s stock grew significantly faster than RGLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGLSXENE
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
75%
Momentum
ODDS (%)
Bullish Trend 12 days ago
89%
Bearish Trend 12 days ago
84%
MACD
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
85%
Bearish Trend 12 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 20 days ago
73%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 12 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
89%
Bullish Trend 12 days ago
76%
Aroon
ODDS (%)
Bullish Trend 12 days ago
89%
Bullish Trend 12 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with ABEO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
+0.25%
ABEO - RGLS
43%
Loosely correlated
-2.12%
NKTX - RGLS
32%
Poorly correlated
+1.15%
NAUT - RGLS
31%
Poorly correlated
-3.95%
ATOS - RGLS
31%
Poorly correlated
-3.13%
XENE - RGLS
30%
Poorly correlated
-3.29%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with ATXS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-3.29%
ATXS - XENE
54%
Loosely correlated
+6.85%
IDYA - XENE
54%
Loosely correlated
+0.72%
CRNX - XENE
53%
Loosely correlated
+1.39%
KYMR - XENE
51%
Loosely correlated
+2.35%
RCKT - XENE
50%
Loosely correlated
+6.44%
More